NEC OncoImmunity Acquires VAXIMM's Neoantigen Vaccine Development Assets
Published on: Tuesday 08 March 2022
Oslo (Norway)/Tokyo (Japan) and Basel (Switzerland)/Mannheim (Germany), Mar 9, 2022 - (JCN Newswire) - NEC OncoImmunity (NOI), a subsidiary of NEC Corporation (NEC), and VAXIMM AG, a Swiss/German biotech company focused on developing an oral plug and play DNA vaccination technology to stimulate patients' cytotoxic T-cells targeting a wide range of cancer-related antigens, today announced that the companies have signed...
News source: https://www.asiaone.com/business/nec-oncoimmunity-acquires-vaximms-neoantigen-vaccine-development-assets
»
Südzucker AG: Südzucker expects significant year-on-year earnings growth also in the second quarter
